(NASDAQ: MGTX) Meiragtx Holdings's forecast annual revenue growth rate of -59.55% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.51%.
Meiragtx Holdings's revenue in 2026 is $397,501,000.On average, 8 Wall Street analysts forecast MGTX's revenue for 2026 to be $33,071,445,243, with the lowest MGTX revenue forecast at $30,563,762,617, and the highest MGTX revenue forecast at $35,973,864,582. On average, 7 Wall Street analysts forecast MGTX's revenue for 2027 to be $8,032,459,927, with the lowest MGTX revenue forecast at $3,764,885,443, and the highest MGTX revenue forecast at $16,932,380,195.
In 2028, MGTX is forecast to generate $8,136,090,320 in revenue, with the lowest revenue forecast at $4,706,490,976 and the highest revenue forecast at $11,708,601,642.